The senolytic ABT-263 improves cognitive functions in middle-aged male, but not female, atherosclerotic LDLr-/-;hApoB100+/+ mice.

Geroscience · 2025 · PMC12181456 · PMID 39982668

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

1 C), did not reach statistical significance (6-mo placebo D5: 22 ± 5 s vs.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

The senolytic ABT-263 improves cognitive functions in middle-aged male, but not female, atherosclerotic LDLr&lt;sup&gt;-/-&lt;/sup&gt;;hApoB&lt;sub&gt;100&lt;/sub&gt;&lt;sup&gt;+/+&lt;/sup&gt; mice.

The sentences

The senolytic ABT-263 improves cognitive functions in middle-aged male, but not female, atherosclerotic LDLr<sup>-/-</sup>;hApoB<sub>100</sub><sup>+/+</sup> mice.